Compile Data Set for Download or QSAR
maximum 50k data
Report error Found 176 Enz. Inhib. hit(s) with all data for entry = 11913
TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandPNGBDBM660485(US20240092799, Compound XXIX-AAM)
Affinity DataIC50:  5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandPNGBDBM660486(US20240092799, Compound XXIX-AAN)
Affinity DataIC50:  5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandPNGBDBM660487(US20240092799, Compound XXIX-AAO)
Affinity DataIC50:  5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandPNGBDBM660488(US20240092799, Compound XXIX-AAP)
Affinity DataIC50:  5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandPNGBDBM660489(US20240092799, Compound XXIX-AAQ)
Affinity DataIC50:  5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandPNGBDBM660490(US20240092799, Compound XXIX-AAR)
Affinity DataIC50:  5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandPNGBDBM660491(US20240092799, Compound XXIX-AAS)
Affinity DataIC50:  5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandPNGBDBM660493(US20240092799, Compound XXXI)
Affinity DataIC50:  5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandPNGBDBM660494(US20240092799, Compound XXXI-A)
Affinity DataIC50:  5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetMAP kinase-interacting serine/threonine-protein kinase 1(Human)
Hepagene Therapeutics (Hk

US Patent
LigandPNGBDBM660325(US20240092799, Compound IIa)
Affinity DataIC50:  5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandPNGBDBM660325(US20240092799, Compound IIa)
Affinity DataIC50:  5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetMAP kinase-interacting serine/threonine-protein kinase 1(Human)
Hepagene Therapeutics (Hk

US Patent
LigandPNGBDBM660326(US20240092799, Compound IIb)
Affinity DataIC50:  5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandPNGBDBM660326(US20240092799, Compound IIb)
Affinity DataIC50:  5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandPNGBDBM660333(US20240092799, Compound X-C)
Affinity DataIC50:  5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandPNGBDBM660337(US20240092799, Compound XVII)
Affinity DataIC50:  5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandPNGBDBM660338(US20240092799, Compound XVII-A | US20240092799, Co...)
Affinity DataIC50:  5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandPNGBDBM660339(US20240092799, Compound XVII-B)
Affinity DataIC50:  5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandPNGBDBM660340(US20240092799, Compound XVII-C)
Affinity DataIC50:  5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandPNGBDBM660348(US20240092799, Compound XX-D)
Affinity DataIC50:  5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandPNGBDBM660351(US20240092799, Compound XXI-A)
Affinity DataIC50:  5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandPNGBDBM660356(US20240092799, Compound XXIII-C)
Affinity DataIC50:  5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandPNGBDBM660363(US20240092799, Compound XXIII-J)
Affinity DataIC50:  5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandPNGBDBM660369(US20240092799, Compound XXIII-P)
Affinity DataIC50:  5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandPNGBDBM660373(US20240092799, Compound XXIII-T)
Affinity DataIC50:  5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandPNGBDBM660374(US20240092799, Compound XXIII-U)
Affinity DataIC50:  5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandPNGBDBM660378(US20240092799, Compound XXIII-Y)
Affinity DataIC50:  5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandPNGBDBM660381(US20240092799, Compound XXIV-A)
Affinity DataIC50:  5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandPNGBDBM660382(US20240092799, Compound XXIV-B | US20240092799, Co...)
Affinity DataIC50:  5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandPNGBDBM660382(US20240092799, Compound XXIV-B | US20240092799, Co...)
Affinity DataIC50:  5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandPNGBDBM660387(US20240092799, Compound XXIV-G)
Affinity DataIC50:  5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandPNGBDBM660389(US20240092799, Compound XXIV-I)
Affinity DataIC50:  5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandPNGBDBM660391(US20240092799, Compound XXIV-K)
Affinity DataIC50:  5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandPNGBDBM660401(US20240092799, Compound XXVIII)
Affinity DataIC50:  5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandPNGBDBM660338(US20240092799, Compound XVII-A | US20240092799, Co...)
Affinity DataIC50:  5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandPNGBDBM660403(US20240092799, Compound XXVIII-B)
Affinity DataIC50:  5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandPNGBDBM660404(US20240092799, Compound XXVIII-C)
Affinity DataIC50:  5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandPNGBDBM660408(US20240092799, Compound XXVIII-G)
Affinity DataIC50:  5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandPNGBDBM660409(US20240092799, Compound XXVIII-H)
Affinity DataIC50:  5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandPNGBDBM660412(US20240092799, Compound XXVIII-K)
Affinity DataIC50:  5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandPNGBDBM660413(US20240092799, Compound XXVIII-L)
Affinity DataIC50:  5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandPNGBDBM660414(US20240092799, Compound XXVIII-M)
Affinity DataIC50:  5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandPNGBDBM660416(US20240092799, Compound XXVIII-O)
Affinity DataIC50:  5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandPNGBDBM660417(US20240092799, Compound XXVIII-P)
Affinity DataIC50:  5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandPNGBDBM660418(US20240092799, Compound XXVIII-Q)
Affinity DataIC50:  5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandPNGBDBM660419(US20240092799, Compound XXVIII-R)
Affinity DataIC50:  5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandPNGBDBM660420(US20240092799, Compound XXIX)
Affinity DataIC50:  5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandPNGBDBM660421(US20240092799, Compound XXIX-A)
Affinity DataIC50:  5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandPNGBDBM660424(US20240092799, Compound XXIX-AN | US20240092799, C...)
Affinity DataIC50:  5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandPNGBDBM660426(US20240092799, Compound XXIX-F)
Affinity DataIC50:  5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandPNGBDBM660427(US20240092799, Compound XXIX-G)
Affinity DataIC50:  5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


Displayed 1 to 50 (of 176 total ) | Next | Last >>
Jump to: